SLBT SL Science Holding Limited
Distress ·
SL Science Holding completed its merger with Horizon Space Acquisition II on June 12, 2026. Its shell company report says its three product candidates are still in preclinical testing, and that its financial statements carry a going-concern warning.
SL Science Holding's F-4 says the blank-check company's trust holds $69,000,000 and that its chairman would control about 58% of the voting power of the combined company. The target's main products include cancer drugs that the filing does not show as approved.
SL Science Holding Limited is a Cayman Islands holding company that conducts its business through its subsidiary, SL Bio. The company describes itself as a biomedical company developing cellular and gene therapies, with a focus on regenerative medicine and cancer treatment. Its lead program is CD-19 Armed-T therapy, which uses bispecific antibodies to equip T cells, without genetic modification, to target blood cancers such as leukemia and lymphoma. The Armed-T technology is licensed from CytoArm Co., Ltd, a company registered in Taiwan, and the licensed patent applications have not yet been granted. A second program uses gamma delta T cell expansion technology, with work aimed at pancreatic and brain cancer models. The company hopes to use bovine-derived milk exosomes to regenerate damaged tissues, and it has exosome applications in skincare and cancer recovery. It expects to gradually phase out its legacy exosome cosmetic and plant supplement businesses as its cell therapies mature. All three product candidates are described as in pre-clinical trials, and the company has not submitted an IND application to the FDA. Its business model centres on partnerships with biopharmaceutical companies.
| Product or program | What it is | Stage |
|---|---|---|
| CD-19 Armed-T Therapy | Engineered T cells with bispecific antibodies targeting CD-19 in blood cancers | pre-clinical trials |
| GDT cell therapy | Expanded gamma delta T cells tested against pancreatic and brain cancer models | pre-clinical trials |
| Exosome cosmetic and plant supplement businesses | Legacy exosome cosmetic and plant supplement lines |
Our latest story on this, dated Jun 18, 2026: "SL Science closes Horizon Space Acquisition II deal, files shell company report". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 18, 2026: "SL Science closes Horizon Space Acquisition II deal, files shell company report". The story links the filing or release it is based on. Read the story.
SL Science Holding Limited trades under the ticker SLBT on NASDAQ.
SL Science Holding Limited is listed on NASDAQ.
The SEC Central Index Key (CIK) for SL Science Holding Limited is 2070534. Its filings are on SEC EDGAR.
Our directory records SL Science Holding Limited under Taiwan.
Our directory classifies SL Science Holding Limited as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for SL Science Holding Limited is KYG8191L1169.
aibio.space lists SL Science Holding Limited among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as E9.
SL Science Holding Limited is a Cayman Islands holding company that conducts its business through its subsidiary, SL Bio. The company describes itself as a biomedical company developing cellular and gene therapies, with a focus on regenerative medicine and cancer treatment.
CD-19 Armed-T Therapy: Engineered T cells with bispecific antibodies targeting CD-19 in blood cancers Stage: pre-clinical trials.
GDT cell therapy: Expanded gamma delta T cells tested against pancreatic and brain cancer models Stage: pre-clinical trials.
Our latest story on SL Science Holding, dated Jun 18, 2026: "SL Science closes Horizon Space Acquisition II deal, files shell company report". SL Science Holding completed its merger with Horizon Space Acquisition II on June 12, 2026. Its shell company report says its three product candidates are still in preclinical testing, and that its financial statements carry a going-concern warning. Source.
From our story of Jun 18, 2026: Its shell company report says its three product candidates are still in preclinical testing, and that its financial statements carry a going-concern warning. Source.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio